[go: up one dir, main page]

NO20043852L - Heterocykliske amidderivater som inhibitorer av glykogen fosforylase - Google Patents

Heterocykliske amidderivater som inhibitorer av glykogen fosforylase

Info

Publication number
NO20043852L
NO20043852L NO20043852A NO20043852A NO20043852L NO 20043852 L NO20043852 L NO 20043852L NO 20043852 A NO20043852 A NO 20043852A NO 20043852 A NO20043852 A NO 20043852A NO 20043852 L NO20043852 L NO 20043852L
Authority
NO
Norway
Prior art keywords
inhibitors
amide derivatives
glycogen phosphorylase
heterocyclic amide
heterocyclic
Prior art date
Application number
NO20043852A
Other languages
English (en)
Inventor
Paul Robert Owen Whittamore
Andrew Stocker
Alan Martin Birch
Andrew David Morley
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20043852L publication Critical patent/NO20043852L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
NO20043852A 2002-03-06 2004-09-14 Heterocykliske amidderivater som inhibitorer av glykogen fosforylase NO20043852L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0205165.4A GB0205165D0 (en) 2002-03-06 2002-03-06 Chemical compounds
PCT/GB2003/000877 WO2003074532A1 (en) 2002-03-06 2003-03-04 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase

Publications (1)

Publication Number Publication Date
NO20043852L true NO20043852L (no) 2004-09-14

Family

ID=9932329

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043852A NO20043852L (no) 2002-03-06 2004-09-14 Heterocykliske amidderivater som inhibitorer av glykogen fosforylase

Country Status (18)

Country Link
US (2) US7129249B2 (no)
EP (1) EP1483270A1 (no)
JP (1) JP2005526058A (no)
KR (1) KR20040096661A (no)
CN (1) CN100384852C (no)
AR (1) AR038888A1 (no)
AU (1) AU2003214377A1 (no)
BR (1) BR0308146A (no)
CA (1) CA2477667A1 (no)
GB (1) GB0205165D0 (no)
IL (1) IL163803A0 (no)
MX (1) MXPA04008614A (no)
NO (1) NO20043852L (no)
NZ (1) NZ534990A (no)
PL (1) PL372973A1 (no)
TW (1) TW200305412A (no)
WO (1) WO2003074532A1 (no)
ZA (1) ZA200406679B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003265681A1 (en) * 2002-08-29 2004-03-19 Merck And Co., Inc. Indoles having anti-diabetic activity
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0320422D0 (en) * 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
BRPI0418244A (pt) 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
JP2007519648A (ja) * 2004-01-31 2007-07-19 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ７−フェニルアミノ−４−キノロン−３−カルボン酸誘導体、その製造方法及び医薬としての使用
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
DE102005063244A1 (de) * 2005-12-21 2007-06-28 Eberhard-Karls-Universität Tübingen Modifiziertes 2-Nitroimidazol-Derivat
ES2566479T3 (es) 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
WO2007082026A2 (en) * 2006-01-10 2007-07-19 The Trustees Of Boston College Catalytic enantioselective silylations of substrates
EP2013835B1 (en) 2006-03-31 2015-11-04 Sunovion Pharmaceuticals Inc. Preparation of chiral amides and amines
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CN103936605B (zh) 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
TW201125566A (en) * 2009-10-16 2011-08-01 Rib X Pharmaceuticals Inc Antimicrobial compounds and methods of making and using the same
CA2777739A1 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
JP2018507881A (ja) 2015-03-11 2018-03-22 メリンタ セラピューティクス，インコーポレイテッド 抗微生物化合物ならびにこれらを作製および使用する方法
EP3452479A1 (en) 2016-05-06 2019-03-13 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
CN109553580B (zh) * 2017-09-25 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物中间体及其盐的制备方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE200740C (no)
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
JPH02124756A (ja) 1988-07-27 1990-05-14 Suzuki Sangyo Kk セメンティング組成物
JPH04179949A (ja) 1990-11-15 1992-06-26 Fuji Photo Film Co Ltd 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料
JP2668003B2 (ja) 1992-06-12 1997-10-27 ファイザー インク． ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤
ES2081747B1 (es) 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
ATE243196T1 (de) 1994-03-09 2003-07-15 Novo Nordisk As Piperidine und pyrrolidine
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
DE4445968A1 (de) 1994-12-22 1996-06-27 Bayer Ag Verwendung von Sulfonylguanazinen
AP624A (en) 1995-06-06 1997-12-19 Pfizer Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
CA2342471C (en) 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
ES2164151T3 (es) 1995-06-06 2002-02-16 Pfizer N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa.
EP1040827A3 (en) 1995-09-08 2000-10-11 Novo Nordisk A/S Use of 2-alkylpyrrolidines for the treatment of diabetes
AU2090897A (en) 1996-02-29 1997-09-16 Mikael Bols Hydroxyhexahydropyridazines
US6069162A (en) 1996-05-27 2000-05-30 Fujisawa Pharmaceutical Co., Ltd. Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
EP0973738A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S Novel heterocyclic compounds
EP0983239A1 (en) 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
AU2535700A (en) 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
US6043091A (en) 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
EP1220832A1 (en) 1999-09-29 2002-07-10 Novo Nordisk A/S Novel aromatic compounds
PT1088824E (pt) 1999-09-30 2004-04-30 Pfizer Prod Inc Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
CZ20021548A3 (cs) 1999-11-05 2002-10-16 Societe De Conseils De Recherches Et D'application Nové heterocyklické sloučeniny a jejich pouľití jako léků
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AR028253A1 (es) 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
EP1145717B1 (en) 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone
TR200401029T4 (tr) 2000-06-09 2004-06-21 Aventis Pharma Deutschland Gmbh Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
AU2001288110A1 (en) 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US6933317B2 (en) 2000-11-01 2005-08-23 Shionogi & Co. Ltd. PGD2 receptor antagonistic pharmaceutical compositions
AU2002256053A1 (en) 2001-04-04 2002-10-21 Genzyme Corporation Novel bgp compounds for therapy and diagnosis and methods for using same
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
WO2003037864A1 (en) 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
US20050009815A1 (en) 2001-11-27 2005-01-13 Devita Robert J. 4-Aminoquinoline compounds
MXPA03000966A (es) 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003227360A1 (en) 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
WO2004041780A2 (en) 2002-11-07 2004-05-21 Pfizer Products Inc. N-(indole-2-carbonyl) amides as anti-diabetic agents
US7098235B2 (en) * 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
JP2004196702A (ja) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
US7501440B2 (en) * 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
WO2004092158A1 (en) 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
MXPA05011702A (es) * 2003-04-30 2006-01-23 Pfizer Prod Inc Agentes antidiabeticos.
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
GB0318464D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318463D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
WO2005020985A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
AR038888A1 (es) 2005-02-02
US20050131015A1 (en) 2005-06-16
BR0308146A (pt) 2004-12-07
WO2003074532A1 (en) 2003-09-12
CN1653070A (zh) 2005-08-10
CA2477667A1 (en) 2003-09-12
IL163803A0 (en) 2005-12-18
TW200305412A (en) 2003-11-01
NZ534990A (en) 2006-02-24
US7129249B2 (en) 2006-10-31
GB0205165D0 (en) 2002-04-17
JP2005526058A (ja) 2005-09-02
EP1483270A1 (en) 2004-12-08
ZA200406679B (en) 2005-01-18
US7276517B2 (en) 2007-10-02
AU2003214377A1 (en) 2003-09-16
CN100384852C (zh) 2008-04-30
KR20040096661A (ko) 2004-11-16
PL372973A1 (en) 2005-08-08
MXPA04008614A (es) 2004-12-06
US20070043069A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
NO20043852L (no) Heterocykliske amidderivater som inhibitorer av glykogen fosforylase
NO20045220L (no) Heterocykliske inhibitorer for kinaser
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
ATE370142T1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
NO20043726L (no) Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
NL300784I2 (nl) Ketorolac, of het trometamolzout ervan, en fenylefrine, of het hydrochloridezout ervan
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
NO20050077L (no) Substituerte heterocykliske derivater som er anvendelige som antidiabetes- og antiovervektsmidler
NO20043587L (no) Nye heterocykliske forbindelser som er aktive som inhibitorer av beta-laktamaser
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
SI1562902T1 (sl) 2-piridonski derivati kot inhibitorji nevtrofilneelastaze
ATE346072T1 (de) Heterozyklische amidderivate mit glykogen- phosphorylase-hemmender wirkung
NO20053546D0 (no) Triazolderivater som inhibitorer av 11-beta-hydroksysteroiddehydrogenase-1.
AU2003303231A1 (en) Benzoxazines and derivatives thereof as inhibitors of pi3ks
ATE369356T1 (de) Pyridazinon-derivate als cdk2-hemmer
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
ATE398107T1 (de) N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme
IS7435A (is) Indólamíðafleiður sem búa yfir tálmavirkni gegn glýkógenfosfórýlasa
AU2003216991A8 (en) Indole amide derivatives and their use as glycogen phosphorylase inhibitors
ATE389658T1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
ZA200509321B (en) Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application